Koers Refocus Group, Inc. Other OTC
Aandelen
RFCS
US75865X2027
Biotechnologie & Medisch Onderzoek
Omzet 2003 | - | Omzet 2004 | - | Marktkapitalisatie | 2,59 mln. 2,41 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2003 | -5 mln. -4,65 mln. | Nettowinst (verlies) 2004 | -3 mln. -2,79 mln. | EV/omzet 2003 | - |
Nettoliquiditeiten 2003 | 3 2,79 | Nettoschuld 2004 | 0,28 0,26 | EV/omzet 2004 | - |
K/w-verhouding 2003 |
-1,51
x | K/w-verhouding 2004 |
-0,67
x | Werknemers | - |
Dividendrendement 2003 * |
-
| Dividendrendement 2004 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
J. Michael Judy
CEO | Chief Executive Officer | - | 28-10-13 |
David Schanzlin
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-12 |
Selene A. Burke
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-06 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 76 | 01-01-11 | |
Thomas M. Loarie
CHM | Chairman | - | 01-01-14 |
Thomas Lyles
BRD | Director/Board Member | - | 01-03-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |